Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

SoFi’s Business Model & Strong Execution Make This Analyst Remain Bullish

After meeting with SoFi Technologies, Inc (NASDAQ:SOFI) CFO at the firm’s Annual Software Summit, Mizuho analyst Dan Dolev reiterated a Buy rating…
byAnusuya Lahiri
September 29, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0
  • After meeting with SoFi Technologies, Inc (NASDAQ:SOFI) CFO at the firm’s Annual Software Summit, Mizuho analyst Dan Dolev reiterated a Buy rating and $8 price target.
  • Also Read: Analyst Upgrades SoFi Technologies, Says Potential Student Loan Refinancing Boom Is Coming
  • He was encouraged to learn more about the resiliency of its high-FICO borrowers; hedging measures; low loan losses and delinquency rates; Galileo’s unique transaction-based pricing model offering protection against a weaker economy; renewed opportunities in student loan refinancing despite recent debt forgiveness; and, the expected roll-off of the PSU SBC burden in 1Q 2024. 
  • Overall, he continues to believe in SOFI’s resilient business model & strong execution.
  • Price Action: SOFI shares traded lower by 6.76% at $4.89 on the last check Thursday.
 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

ADC Therapeutics Announced Initial Safety Run‐In Results From Lotis-5 Phase 3 Trial Demonstrate ORR Of 75% & 40% CR Rate With No New Safety Signals

By Charles Gross
September 21, 8:02 PM
ADC Therapeutics SA (NYSE: ADCT) today announced that ZYNLONTA® (loncastuximab tesirine-lpyl) and camidanlumab tesirine (Cami) abstracts have been accepted for presentation at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022), which will be held in Houston, Texas from September 28–October 1, 2022.

ADCT